Dr. Felicia Pagliuca is the Disease Area Executive, Type 1 Diabetes, at Vertex Pharmaceuticals, and a part of the leadership team of Vertex Cell and Genetic Therapies (VCGT). Previously, Dr. Pagliuca served as co-founder and Vice President of Cell Biology R&D at Semma Therapeutics. Semma Therapeutics was acquired by Vertex in 2019. Dr. Pagliuca received a B.S. from Duke University, and a Ph.D. from Cambridge University where she was a Marshall Scholar. She completed her postdoctoral fellowship with Dr. Douglas Melton at the Harvard Stem Cell Institute.